Australian patent granted for selected compounds for chronic wound therapy
INJECTHEAL Project kick-off meeting
Full title of the project: “Multifunctional Self-Healing Injectable Hydrogel for Chronic Wound Healing and Tissue Regeneration”
Akribes is part of the INJECTHEAL consortium, which consists of 13 partners from 8 European countries (Italy, Austria, Germany, Ireland, Spain, Switzerland, and the UK), with the aim of contributing to the advancement of knowledge and applications in the field of chronic wound healing.
At the heart of the project is the development of a 4D injectable self-healing hydrogel, designed for the targeted release of medications into complex wounds, contributing to the reduction of inflammation and infection and supporting tissue regeneration. The hydrogel will be developed using sustainable materials, with the goal of providing an advanced therapeutic option, particularly for deep cavity wounds.
INJECTHEAL is funded by the European Union through the Horizon Europe research and innovation programme (project duration: three years).
Please follow the project on LinkedIn @INJECTHEAL Project and Instagram @injectheal.project.
Cabral G, Schoefmann N, Wolff-Winiski B (2025)
CHANGES IN THE PROTEOME INDICATE A SPECIFIC ROLE OF STAT-4 IN MEDIATING THE FIBROBLAST INFLAMMATORY RESPONSE TO CHRONIC WOUND EXUDATE.
Poster at the 35th Conference of the European Wound Management Association, the EWMA - GNEAUPP 2025 CONFERENCE, March 26-28, 2025, Barcelona, Spain
2025-03b EWMA oral presentation
Wolff-Winiski B, Schoefmann N, Doerfler P, Cabral G, Stuetz A (2025)
Identification of AKR101 as potential new drug for chronic wound therapy.
Oral presentation at the 35th Conference of the European Wound Management Association, the EWMA - GNEAUPP 2025 CONFERENCE, March 26-28, 2025, Barcelona, Spain
Chinese patent granted for selected compounds for chronic wound therapy
Confirmation of Phase 2-readiness of AKR101-documentation for a clinical study in chronic wound patients.
The Federal Institute for Drugs and Medical Devices in Germany, BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte), confirms in a scientific advice meeting that the documentation of AKR101 is ready for a Phase 2 clinical study in chronic wound patients.
Patent for selected compounds for chronic wound therapy granted in Singapore
Meet us at 4. WundD.A.CH Kongress 2025 in Freiburg, Germany.
Doerfler P, Schoefmann N, Stuetz A, Wolff-Winiski B (2022)
Development of a “theranostic” assay for chronic wounds and identification of compounds with so far unknown potential for treatment of chronic wounds
Oral presentation at the ÖGMBT 2022 Annual Meeting, Sept 19-22, 2022, in Vienna, Austria
Doerfler P, Schoefmann N, Cabral G, Stuetz A, Wolff-Winiski B (2024)
Identification and characterization of potential wound therapeutics based on a new personalized ex vivo wound model.
Poster at the ETRS-WHS-SKINTERM 2024 Annual Meeting, Sept. 24-27, 2024 in Amersfoort, Netherlands